[Combined chemo-hormone therapy in advanced ovarian cancer. Results of the 2d Austrian ovarian cancer study].
Sevelda
P
P
Osterreichische Arbeitsgemeinschaft zur Therapie des Ovarialkarzinoms, Universitäts Frauenklinik Wien.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D015996:Survival Rate
D000970:Antineoplastic Agents; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone
Die kombinierte Chemo-Hormontherapie beim fortgeschrittenen Ovarialkarzinom. Ergebnisse der 2. österreichischen Ovarialkarzinomstudie.